Phase II study of intraperitoneal recombinant interleukin-12 (rhIL-12) in patients with peritoneal carcinomatosis (residual disease < 1 cm) associated with ovarian cancer or primary peritoneal carcinoma.
about
Interleukin 12: still a promising candidate for tumor immunotherapy?Interleukin 12 a key immunoregulatory cytokine in infection applicationsHemaMax™, a recombinant human interleukin-12, is a potent mitigator of acute radiation injury in mice and non-human primatesIL-12 Expressing oncolytic herpes simplex virus promotes anti-tumor activity and immunologic control of metastatic ovarian cancer in mice.Polyfunctional T-cell responses are disrupted by the ovarian cancer ascites environment and only partially restored by clinically relevant cytokines.The role of immunotherapy in solid tumors: report from the Campania Society of Oncology Immunotherapy (SCITO) meeting, Naples 2014The novel, small-molecule DNA methylation inhibitor SGI-110 as an ovarian cancer chemosensitizer.Interleukin-12 preserves the cutaneous physical and immunological barrier after radiation exposure.Abrogation of TNFα production during cancer immunotherapy is crucial for suppressing side effects due to the systemic expression of IL-12.Differential growth inhibition of cerebral metastases by anti-angiogenic compoundsIL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo.A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer.Bladder Cancer Immunotherapy: BCG and Beyond.Interleukin-12 Immunomodulation Delays the Onset of Lethal Peritoneal Disease of Ovarian Cancer.Gene-modified bone marrow cell therapy for prostate cancer.Coexpression of IL-18 strongly attenuates IL-12-induced systemic toxicity through a rapid induction of IL-10 without affecting its antitumor capacity.Evaluating the role of IL-12 based therapies in ovarian cancer: a review of the literature.A phase I trial of intraperitoneal GEN-1, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer, administered with pegylated liposomal doxorubicin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary periMultiplex profiling identifies distinct local and systemic alterations during intraperitoneal chemotherapy for ovarian cancer: An NRG Oncology/Gynecologic Oncology Group Study.Mesothelin-specific cell-based vaccine generates antigen-specific immunity and potent antitumor effects by combining with IL-12 immunomodulator.Phase-I clinical trial of IL-12 plasmid/lipopolymer complexes for the treatment of recurrent ovarian cancer.Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment.Preclinical validation: LV/IL-12 transduction of patient leukemia cells for immunotherapy of AML.Recombinant murine IL-12 promotes a protective Th1/cellular response in Mongolian gerbils infected with Sporothrix schenckii.Plasma Pharmacokinetics of Veledimex, a Small-Molecule Activator Ligand for a Proprietary Gene Therapy Promoter System, in Healthy Subjects.Antitumoral efficacy of DNA nanoparticles in murine models of lung cancer and pulmonary metastasis.
P2860
Q26861559-2C32C5BE-26C6-46B8-A8F1-1869467F89E9Q28395500-2B0EDA66-ABD8-468A-B587-723A76B37C76Q28731776-85582C95-5570-4333-87B7-C5257DC8BCFFQ30355682-3EB41582-C212-472C-9489-2E355C07E5F9Q33784707-45EF321E-3F6D-4C66-8ACF-4492289D428BQ34402325-06EFE5D6-A664-4A40-9210-B0A04502E3F7Q34717933-90EA0E0E-60DB-41ED-A955-79AD86403C03Q35013265-443F48BD-CEAD-43D3-9620-E1454B6E0FCFQ35108695-EB9CAF0D-B112-4312-8FC1-744DE7AD3DAFQ35304863-EED2FEC6-C3F8-4638-B242-B9B418A10B16Q35506724-A6D92C5E-E17D-40C8-9BC2-F70C2F1BE447Q35627284-305C3025-6BA2-4523-8F89-6A442BFE2C30Q36072179-737DE3D9-ED9A-4259-9DB1-FF5C527621A5Q36489567-64B7ECC0-0906-4E54-B7B3-ABE3A97244A3Q37127252-51CCB080-2B47-4628-9A06-2D1F34EB7A9AQ37462813-A5C3266D-A73B-4F09-A583-1551E00DEFEBQ37851520-81F472FC-9750-4B9E-9E88-4C06B11E4E0FQ38627539-78FFF5CF-0A16-4C1D-B3C6-7F115D5AC3BFQ38797393-1289211C-7538-473D-A965-4E46294EF17FQ38844559-50926DE4-D66F-4D92-80DB-2BAF19A27A60Q40370693-BA1FD135-8249-47A0-B80D-4B642417A0ECQ41619752-0169F96B-7F8A-4FF7-B8DF-F6A362B2C490Q41909592-9DCC2A99-193A-498A-BE80-881BE7AE7DD5Q45014276-3371AD1D-C704-4A8B-A08D-62A6E12BB27DQ45855827-37064B7D-F5A1-446C-805C-511D60061DD9Q45886686-AE6EAD7D-C5F5-413A-A34F-88A25E10DC3B
P2860
Phase II study of intraperitoneal recombinant interleukin-12 (rhIL-12) in patients with peritoneal carcinomatosis (residual disease < 1 cm) associated with ovarian cancer or primary peritoneal carcinoma.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Phase II study of intraperiton ...... primary peritoneal carcinoma.
@ast
Phase II study of intraperiton ...... primary peritoneal carcinoma.
@en
type
label
Phase II study of intraperiton ...... primary peritoneal carcinoma.
@ast
Phase II study of intraperiton ...... primary peritoneal carcinoma.
@en
prefLabel
Phase II study of intraperiton ...... primary peritoneal carcinoma.
@ast
Phase II study of intraperiton ...... primary peritoneal carcinoma.
@en
P2093
P2860
P356
P1476
Phase II study of intraperiton ...... primary peritoneal carcinoma.
@en
P2093
Michael E Garcia
Michael Rosenblum
Michael V Seiden
Ralph S Freedman
Renato Lenzi
Robert Edwards
P2860
P2888
P356
10.1186/1479-5876-5-66
P577
2007-12-12T00:00:00Z
P5875
P6179
1043990539